Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advanced testis cancer.

J P Droz1, M Rivoire

  • 1Department of Medical Oncology, Centre Léon-Bérard, 28 rue Laënnec, 68008, Lyon, France. jpdroz@wanadoo.fr

Current Treatment Options in Oncology
|June 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Suprapubic versus transurethral catheterization for bladder drainage in male rectal cancer surgery (GRECCAR10), a randomized clinical trial.

Techniques in coloproctology·2024
Same author

Advanced oesophago-gastric adenocarcinoma in older patients in the era of immunotherapy. A review of the literature.

Cancer treatment reviews·2021
Same author

Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study).

The British journal of surgery·2021
Same author

Early and late morbidity of local excision after chemoradiotherapy for rectal cancer.

BJS open·2021
Same author

Sphincter-saving surgery after neoadjuvant therapy for ultra-low rectal cancer where abdominoperineal resection was indicated: 10-year results of the GRECCAR 1 trial.

The British journal of surgery·2021
Same author

Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer.

ESMO open·2021
Same journal

Interaction between Regulated Cell Death Pathways and Core Cellular Processes: Unraveling the Molecular Mechanisms of Cardiotoxicity of Antitumor Drugs.

Current treatment options in oncology·2026
Same journal

Advances in Immunotherapy for Breast Cancer: Up-to-date Strategies of Immune Checkpoint Inhibitors and Therapeutic Vaccines.

Current treatment options in oncology·2026
Same journal

Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.

Current treatment options in oncology·2026
Same journal

The Immunological Landscape of the Tumor Microenvironment: Implications for Immunotherapy of Unresectable and Metastatic Soft Tissue Sarcomas.

Current treatment options in oncology·2026
Same journal

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.

Current treatment options in oncology·2026
Same journal

Emerging Applications of CAR-T Cell Therapy in Overcoming Resistance and Expanding Targets in Hematologic Malignancies: Insights from Recent Research.

Current treatment options in oncology·2026
See all related articles

Advanced testis tumors are highly curable with chemotherapy and surgery. Treatment involves BEP chemotherapy cycles based on risk, followed by surgical removal of any remaining disease for optimal outcomes.

Area of Science:

  • Oncology
  • Urology

Background:

  • Advanced testis tumors are a highly curable malignancy.
  • Current treatment involves chemotherapy followed by surgical resection of residual disease.

Purpose of the Study:

  • To outline the established treatment strategy for advanced testis tumors.
  • To detail the role of chemotherapy and surgery in managing these cancers.

Main Methods:

  • Standard chemotherapy regimen is BEP (bleomycin, etoposide, cisplatin).
  • Number of chemotherapy cycles is determined by prognostic factors (primary site, histology, metastases, tumor markers).
  • Surgical exeresis of residual disease and retroperitoneal dissection are mandatory post-chemotherapy.

Main Results:

  • Good-risk patients receive three cycles; intermediate- and high-risk patients receive four cycles.

Related Experiment Videos

  • Complete surgical removal of residual disease (necrotic tissue, teratoma, active cancer) obviates further treatment.
  • Multidisciplinary care in specialized centers improves outcomes.

    • Conclusions:

    • Advanced testis tumors are curable with a structured approach.
    • Chemotherapy (BEP) followed by surgical management of residual disease is the standard of care.
    • Expertise in chemotherapy administration and surgical techniques is crucial for successful treatment.